Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Conditions
Interventions
GEN3009
Epcoritamab
Locations
17
United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
March 13, 2020
Primary Completion Date
November 21, 2022
Completion Date
July 28, 2023
Last Updated
October 24, 2024
NCT07545603
NCT06395103
NCT05272384
NCT06149286
NCT06337318
NCT05139017
Lead Sponsor
Genmab
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions